Cencora (NYSE:COR – Get Free Report) is scheduled to announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $3.21 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Cencora Stock Performance
Shares of COR stock opened at $234.27 on Monday. The firm has a market cap of $46.16 billion, a price-to-earnings ratio of 25.44, a P/E/G ratio of 1.45 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora has a 52 week low of $184.00 and a 52 week high of $247.66. The firm’s 50-day simple moving average is $231.39 and its two-hundred day simple moving average is $230.60.
Insiders Place Their Bets
In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.80% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Research Report on Cencora
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
- Five stocks we like better than Cencora
- The 3 Best Retail Stocks to Shop for in August
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- What Does Downgrade Mean in Investing?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.